Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 52.83

-4.4%

10:43 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mike McFarland who wrote (147)	4/9/1999 1:34:00 PM
From: Biomaven	Read Replies (2) of 52153

Mike, OSIP has moved on no announced news. Either there is an institution accumulating, or there is something going on that we don't know about yet. They do have an anti-angiogenesis candidate: CP-564,959 is being developed as an orally available, potent and selective inhibitor of a key protein tyrosine kinase receptor involved in blood vessel growth or angiogenesis. Angiogenesis is induced by solid tumors which require nutrients that will enable growth. The Company believes that the ability to safely and effectively inhibit this process represents one of the most exciting areas of cancer drug development. Don't really know why IMCL has been strong either, except it's now being hyped some. I'm hanging on to my few shares for now. Remember that CELG and SUGN both have had fair runs in the last six months. SUGN is going to need some time to get over the 60 minutes extravaganza, and CELG probably needs to start showing some real sales of Thalomid before it moves. Both good stocks to be patient with. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next